Chronic Total Occlusion (CTO) System
Boston Scientific brings you the one proven system for bridging coronary CTOs via the true lumen or subintimal pathways. CrossBoss™ and Stingray™ Coronary CTO Crossing and Re-Entry devices allow you to treat these complex lesions safely, with maximum efficiency and success.
View the CrossBoss and Stingray Re-Entry System
Safe and Effective
The FAST-CTO trial demonstrated that use of the CrossBoss and Stingray Crossing and Re-Entry devices result in a high technical success, 77%, without increasing complications.1
Reduced Procedure Time
The FAST-CTO trial also showed that procedural success was improved with a 28.1% reduction in mean procedure time (minutes) as well as a reduction in fluoroscopy time.1
1 Whitlow P, Lombardi W, Wyman M et al. Use of Novel Crossing and Re-Entry System in Coronary Chronic Total Occlusions That Have Failed Standard Crossing Techniques.
J Am Coll Cardiol Interv. 2012;5:393-401.
Prior to use, please see the complete "Directions for Use" for more information on Indications, Contraindications, Warnings, Precautions, Adverse Events, and Operator's Instructions.
CrossBoss and Stingray are unregistered trademarks of Boston Scientific Corporation or its affiliates. All other trademarks are the property of their respective owners.